Literature DB >> 13340157

The occurrence of hyperuricemia during pyrazinamide-isoniazid therapy.

J H CULLEN, L J EARLY, J M FIORE.   

Abstract

Entities:  

Keywords:  BLOOD; NICOTINIC ACID ISOMERS/therapeutic use; PYRIMIDINES/therapeutic use; URIC ACID/in blood

Mesh：

Substances：

Year:  1956        PMID： 13340157     DOI： 10.1164/artpd.1956.74.2-1.289

Source DB:  PubMed          Journal:  Am Rev Tuberc        ISSN： 0096-0381


× No keyword cloud information.
  7 in total

1.  Studies of the uricogenic effect of 2-substituted thiadiazoles in man.

Authors:  I H KRAKOFF; M E BALIS
Journal:  J Clin Invest       Date:  1959-06       Impact factor: 14.808

2.  Hyperuricaemia due to pyrazinamide.

Authors:  J SCHNEEWEISS; G W POOLE
Journal:  Br Med J       Date:  1960-09-17

3.  Adverse effects of antituberculosis drugs.

Authors:  D J Girling
Journal:  Drugs       Date:  1982 Jan-Feb       Impact factor: 9.546

Review 4.  Lowering and Raising Serum Urate Levels: Off-Label Effects of Commonly Used Medications.

Authors:  Nicole Leung; Kevin Yip; Michael H Pillinger; Michael Toprover
Journal:  Mayo Clin Proc       Date:  2022-07       Impact factor: 11.104

Review 5.  Treatment of active pulmonary tuberculosis in adults: current standards and recent advances. Insights from the Society of Infectious Diseases Pharmacists.

Authors:  Ronald G Hall; Richard D Leff; Tawanda Gumbo
Journal:  Pharmacotherapy       Date:  2009-12       Impact factor: 4.705

6.  Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.

Authors:  Payam Nahid; Susan E Dorman; Narges Alipanah; Pennan M Barry; Jan L Brozek; Adithya Cattamanchi; Lelia H Chaisson; Richard E Chaisson; Charles L Daley; Malgosia Grzemska; Julie M Higashi; Christine S Ho; Philip C Hopewell; Salmaan A Keshavjee; Christian Lienhardt; Richard Menzies; Cynthia Merrifield; Masahiro Narita; Rick O'Brien; Charles A Peloquin; Ann Raftery; Jussi Saukkonen; H Simon Schaaf; Giovanni Sotgiu; Jeffrey R Starke; Giovanni Battista Migliori; Andrew Vernon
Journal:  Clin Infect Dis       Date:  2016-08-10       Impact factor: 9.079

7.  Identification of Febuxostat as a New Strong ABCG2 Inhibitor: Potential Applications and Risks in Clinical Situations.

Authors:  Hiroshi Miyata; Tappei Takada; Yu Toyoda; Hirotaka Matsuo; Kimiyoshi Ichida; Hiroshi Suzuki
Journal:  Front Pharmacol       Date:  2016-12-27       Impact factor: 5.810
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.